Related Experiment Video
Updated: Jun 21, 2026

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
Published on: May 16, 2021
Lowering industry firewalls: pre-competitive informatics initiatives in drug discovery
Michael R Barnes1, Lee Harland, Steven M Foord
1Department of Computational Biology, GlaxoSmithKline, Third Avenue, Harlow, Essex, UK. Michael.R.Barnes@gsk.com
Abstract:
Pharmaceutical research and development is facing substantial challenges that have prompted the industry to shift funding from early- to late-stage projects. Among the effects is a major change in the attitude of many companies to their internal bioinformatics resources: the focus has moved from the vigorous pursuit of intellectual property towards exploration of pre-competitive cross-industry collaborations and engagement with the public domain. High-quality, open and accessible data are the foundation of pre-competitive research, and strong public-private partnerships have considerable potential to enhance public data resources, which would benefit everyone engaged in drug discovery. In this article, we discuss the background to these changes and propose new areas of collaboration in computational biology and chemistry between the public domain and the pharmaceutical industry.
Related Concept Videos
Drug Discovery: Overview
Preclinical Development: Overview
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Protein-protein Interfaces
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Pharmacogenomics: Identification of New Drug Targets
